0001127602-22-002057.txt : 20220125
0001127602-22-002057.hdr.sgml : 20220125
20220125163732
ACCESSION NUMBER: 0001127602-22-002057
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220121
FILED AS OF DATE: 20220125
DATE AS OF CHANGE: 20220125
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DeLong Mark Jeffrey
CENTRAL INDEX KEY: 0001856078
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38276
FILM NUMBER: 22554355
MAIL ADDRESS:
STREET 1: 100 5TH AVENUE, 3RD FLOOR
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Apellis Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001492422
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 271537290
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 FIFTH AVENUE
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 617-977-5700
MAIL ADDRESS:
STREET 1: 100 FIFTH AVENUE
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2022-01-21
0001492422
Apellis Pharmaceuticals, Inc.
APLS
0001856078
DeLong Mark Jeffrey
C/O APELLIS PHARMACEUTICALS, INC.
100 FIFTH AVENUE, 3RD FLOOR
WALTHAM
MA
02451
1
Senior Vice President
Common Stock
2022-01-21
4
A
0
10592
0
A
20964
D
Stock Option (Right to Buy)
35.46
2022-01-21
4
A
0
15024
0
A
2032-01-20
Common Stock
15024
15024
D
This represents a restricted stock unit grant made on January 21, 2022 that vests 25% annually in equal installments over four years from the date of grant, subject to continued service.
This represents a non-qualified stock option grant made on January 21, 2022 that vests over a four year period with 25% vesting one year from grant date and the remaining 75% vesting in equal monthly installments thereafter through the fourth anniversary of the grant date, subject to continued service.
/s/ David Watson, attorney-in-fact for Mark Delong
2022-01-25